---

---

cln-081  

save search

---

Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients
Published: 2023-10-10 (Crawled : 07:00) - zailaboratory.com
CGEM | $18.42 10.5% 220K |

| 90.51% | O: -1.14% H: 4.86% C: 2.66%
cln-081

---

Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417
Published: 2022-06-23 (Crawled : 12:20) - globenewswire.com
CGEM | $18.42 10.5% 220K |

| 30.95% | O: 1.18% H: 3.65% C: 3.42%
cln-081 collaboration agreement

---

Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting
Published: 2022-05-31 (Crawled : 17:00) - biospace.com/
CGEM | $18.42 10.5% 220K |

| 45.21% | O: 0.44% H: 0.0% C: -7.29%
cln-081 asco potential positive cancer

---

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl
Published: 2022-05-12 (Crawled : 08:00) - biospace.com/
CGEM | $18.42 10.5% 220K |

| 99.64% | O: 8.74% H: 6.5% C: -0.88%
cln-081 acquisition collaboration

---

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients
Published: 2022-03-28 (Crawled : 00:00) - biospace.com/
CGEM | $18.42 10.5% 220K |

| 45.21% | O: 0.26% H: 3.04% C: -2.69%
cln-081

---

Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022
Published: 2022-03-17 (Crawled : 19:00) - biospace.com/
CGEM | $18.42 10.5% 220K |

| 36.08% | O: -2.53% H: 7.62% C: 7.29%
cln-081

---

FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Published: 2022-01-04 (Crawled : 15:00) - biospace.com/
CGEM | $18.42 10.5% 220K |

| 1.09% | O: 3.27% H: 8.4% C: -1.64%
cln-081 fda cel lung cancer therapy cancer breakthrough therapy designation

---

Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients
Published: 2021-12-16 (Crawled : 12:00) - globenewswire.com
CGEM | $18.42 10.5% 220K |

| 6.89% | O: 3.05% H: 3.3% C: -4.42%
cln-081 phase 1 phase 2

---

Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients
Published: 2021-12-13 (Crawled : 14:30) - biospace.com/
CGEM | $18.42 10.5% 220K |

| -0.89% | O: -2.88% H: 0.0% C: 0.0%
cln-081

---

Multimedia Release — Huntington Ingalls Industries Celebrates Ceremonial First Cut of Steel for the Aircraft Carrier Doris Miller (CVN 81)
Published: 2021-08-25 (Crawled : 20:00) - globenewswire.com
HII | $274.1 -0.14% 320K |

Electronic Technology

| 33.1% | O: -0.55% H: 0.11% C: -0.32%
huntington media

---

Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML
Published: 2021-06-07 (Crawled : 13:00) - biospace.com/
CGEM | $18.42 10.5% 220K |

| -49.65% | O: 0.27% H: 4.48% C: 1.99%
new drug treatment fda antibody drug clearance aml

---

Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China
Published: 2020-12-28 (Crawled : 13:00) - globenewswire.com
ZLAB | $15.61 3.24% 190K |

Health Technology

| -88.7% | O: 0.23% H: 0.18% C: -2.79%
china collaboration license

---

Gainers vs Losers

54%

46%

Top 10 Gainers

CSSE 4 | $0.3499 129.74% 150M |

Consumer Services

CZOO | $11.04 121.24% 9.6M |

BOF | $2.05 75.21% 78M |

AMST | $3.2 60.0% 63M |

Technology Services

LICN | $0.8592 53.43% 13M |

WIMI | $1.05 44.75% 13M |

Technology Services

TROO | $1.51 38.53% 5.6M |

Manufacturing

MULN | News | $3.675 34.62% 11M |

Information

RILY | $28.605 31.7% 9.9M |

Finance

RBBN 4 | $3.305 28.6% 1.9M |

Electronic Technology

---

Your saved searches

---